Revenues

12 Months Ended

Dec. 31, 2018

Revenue from Contract with Customer [Abstract]

Revenue from Contract with Customer [Text Block]

REVENUES

Disaggregation of Revenues

The following table disaggregates our product sales by product and geographic region and disaggregates our royalty, contract and other revenues by geographic region for the years ended December 31, 2018, 2017 and 2016. The information for the years ended December 31, 2017 and 2016 has not been adjusted in accordance with our modified retrospective adoption of Topic 606 and continues to be reported in accordance with our historical accounting under Topic 605.

	Year Ended December 31, 2018								Year Ended December 31, 2017								Year Ended December 31, 2016
(In millions)	U.S.		Europe		Other International		Total		U.S.		Europe		Other International		Total		U.S.		Europe		Other International		Total
Product Sales:
Atripla	$	967	$	131	$	108	$	1,206	$	1,288	$	335	$	183	$	1,806	$	1,898	$	520	$	187	$	2,605
Biktarvy	1,144		39		1		1,184		—		—		—		—		—		—		—		—
Complera/Eviplera	276		327		50		653		406		503		57		966		821		580		56		1,457
Descovy	1,217		308		56		1,581		958		226		34		1,218		226		69		3		298
Genvoya	3,631		794		199		4,624		3,033		534		107		3,674		1,301		160		23		1,484
Odefsey	1,242		335		21		1,598		964		132		10		1,106		302		27		—		329
Stribild	505		97		42		644		811		195		47		1,053		1,523		314		77		1,914
Truvada	2,605		260		132		2,997		2,266		644		224		3,134		2,384		913		269		3,566
Other HIV(1)	40		7		14		61		43		6		9		58		41		6		—		47
Revenue share - Symtuza(2)	27		52		—		79		—		—		—		—		—		—		—		—
AmBisome	46		229		145		420		28		207		131		366		20		209		127		356
Epclusa	934		654		378		1,966		2,404		869		237		3,510		1,591		141		20		1,752
Harvoni	802		144		276		1,222		3,053		704		613		4,370		4,941		1,810		2,330		9,081
Letairis	943		—		—		943		887		—		—		887		819		—		—		819
Ranexa	758		—		—		758		717		—		—		717		677		—		—		677
Vemlidy	245		12		64		321		111		5		6		122		3		—		—		3
Viread	50		82		175		307		514		238		294		1,046		591		302		293		1,186
Vosevi	304		78		14		396		267		22		4		293		—		—		—		—
Yescarta	263		1		—		264		7		—		—		7		—		—		—		—
Zydelig	61		70		2		133		69		77		3		149		91		76		1		168
Other(3)	137		76		107		320		283		314		583		1,180		2,036		949		1,226		4,211
Total product sales	16,197		3,696		1,784		21,677		18,109		5,011		2,542		25,662		19,265		6,076		4,612		29,953
Royalty, contract and other revenues	72		310		68		450		85		300		60		445		89		289		59		437
Total revenues	$	16,269	$	4,006	$	1,852	$	22,127	$	18,194	$	5,311	$	2,602	$	26,107	$	19,354	$	6,365	$	4,671	$	30,390

____________________
Notes:
(1)	Includes Emtriva and Tybost
(2)	Represents Gilead’s revenue from cobicistat (C), emtricitabine (FTC) and tenofovir alafenamide (TAF) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland UC (Janssen)
(3)	Includes Cayston, Hepsera and Sovaldi

Revenues Recognized from Performance Obligations Satisfied in Prior Periods

During the year ended December 31, 2018, revenues recognized from performance obligations satisfied in prior years related to royalties for licenses of our intellectual property were $541 million. Changes in estimates for variable consideration related to sales made in prior years resulted in a $56 million decrease in revenues during the year ended December 31, 2018.

Contract Balances

Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $125 million and $132 million as of December 31, 2018 and January 1, 2018, respectively.

Contract liabilities were not material as of December 31, 2018 and January 1, 2018.